ProPhase Labs, Inc. Interest and Fee Income, Loans and Leases
ProPhase Labs, Inc. (PRPH) reported Interest and Fee Income, Loans and Leases of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InterestAndFeeIncomeLoansAndLeases · last filed 2023-03-29
- ProPhase Labs, Inc. interest and fee income, loans and leases for the quarter ending 2021-12-31 was $111.00K.
- ProPhase Labs, Inc. interest and fee income, loans and leases for the quarter ending 2021-09-30 was $230.00K.
- ProPhase Labs, Inc. interest and fee income, loans and leases for the quarter ending 2021-06-30 was $0.00.
- ProPhase Labs, Inc. interest and fee income, loans and leases for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ProPhase Labs, Inc. interest and fee income, loans and leases for fiscal 2021 was $642.00K, a 935.48% increase from fiscal 2020.
- ProPhase Labs, Inc. interest and fee income, loans and leases for fiscal 2020 was $62.00K.
| Period end | Interest and Fee Income, Loans and Leases 3 month | Interest and Fee Income, Loans and Leases 6 month | Interest and Fee Income, Loans and Leases 9 month | Interest and Fee Income, Loans and Leases 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-29 | |||
| 2021-12-31 | $111.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $341.00K derived: sum of 2 quarters · filed 2023-03-29 | $341.00K derived: sum of 3 quarters · filed 2023-03-29 | $642.00K 10-K · filed 2023-03-29 |
| 2021-09-30 | $230.00K 10-Q · filed 2021-11-12 | $230.00K derived: sum of 2 quarters · filed 2021-11-12 | $531.00K 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-13 | $233.00K 10-Q · filed 2021-08-13 | ||
| 2020-12-31 | $62.00K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |